

Clatterbridge Road Bebington Wirral CH63 4JY

Tel: 0151 556 5000 Web: www.clatterbridgecc.nhs.uk

Date: 16 July 2018

Re: Freedom of Information Request Ref: 129-2018

Thank you for your email dated 19th June 2018, requesting information regarding medicines.

The information that you require is as follows:

1 - In your Trust, how much did you spend on Biological and biosimilar medicines, in the past financial year ending April 2018?

Trastuzumab / Kadcyla - £7,431,846

Cetuximab - £1,500,846

Pertuzumab - £3,336,126

Filgrastim - £115,113

Rituximab (Mabthera) - £313,578

Rituximab (biosimilar) - £194,582

2 – Have you developed a policy on how prescribers can switch their patients to biosimilars and support them in making informed choices to save resources?

Policy development is currently in progress.

If yes, please provide details

3 – Do you have any specific plans in place for the launch of biosimilar Adalimumab later in 2018?

N/A as we are a tertiary specialist cancer treatment centre.

4 – Are there any agreements in place between you the Provider and CCG that would enable savings in drug costs to be made? (For example, Gainshare agreements where the benefits associated with more efficient use of medicines not reimbursed through national prices is shared between the Provider and the Clinical Commissioning Group party to the agreement. This included agreements for the switch to biosimilar products) If "Yes", then please provide the following details:

Agreement Name of specific drugs involved Disease

Area CCG(s) included in the Gainshare agreement Savings
apportioned between Provider and the CCG(s)

- 1 Infliximab
- 2 Etanercept
- 3 Rituximab
- 4 Adalimumab
- 5 Trastuzumab

6

7

No, there are no gain share agreements currently in place. All savings are passed through to the commissioners.

The Biosimilar switch is part of the trigger 1 medicines optimisation CQUIN year 1 (17/18), year 2 (18/19).

5 – Are there any other agreements with a CCG, not included in the above, for the following services?

No

If "Yes", then please provide the following details:

N/A

Agreement Disease Area CCG(s) included in the agreement Name of specific drugs involved Type of agreement with the Provider

- 1 Ophthalmology services (e.g. wet macular degeneration)
- 2 Multiple Sclerosis
- 3 Prostate Cancer
- 4 Breast Cancer
- 5 Haemophilia

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be

Version: 1.0 Ref: ECGMFOIRE addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

https://www.surveymonkey.co.uk/r/H39RFMM

Version: 1.0 Ref: ECGMFOIRE